Navigation Links
Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
Date:8/3/2011

LONDON, August 3, 2011 /PRNewswire/ --

Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, announces that the United States Patent and Trademark Office has issued the Company a notice of allowance on a patent application directed to the fundamental technology involved in AtuPLEX™, one of Silence's proprietary small interfering RNA (siRNA) delivery systems. The allowable subject matter is directed to AtuFect, the specific proprietary lipid that serves as the basis for the AtuPLEX delivery system, and provides proprietary protection for one of the RNAi industry's most clinically advanced and promising delivery technologies. These claims will cover the delivery system incorporated in Silence's lead clinical compound, Atu027, as well as a number of the Company's other RNAi therapeutic candidates.

"This is a highly valuable patent. Not only does it provide direct protection for AtuPLEX, one of the most advanced and exciting solutions addressing the challenge of delivering siRNAs, but also adds key layers of protection for our pipeline of RNAi therapeutics, including our lead RNAi therapeutic candidate, Atu027," said Max Herrmann, Chief Financial Officer of Silence Therapeutics."This notice of allowance follows the recent presentation of data from our ongoing clinical study of Atu027 at the 2011 American Society of Clinical Oncology conference which showed that the treatment, and therefore the AtuPLEX delivery technology, is safe and well-tolerated in all patients."

At the 2011 American Society of Clinical Oncology annual meeting, Silence presented interim Phase I clinical study results that showed promising antitumor activity associated with Atu027, as well as demonstrating that the treatment is well tolerated with no observed dose-limiting toxicities or evidence of cytokine activation. Favorable pharmacokinetic
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Silence Therapeutics Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting
2. Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials
3. Silence Therapeutics Provides Year-end Update
4. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
5. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
6. Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
7. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
8. Silence Therapeutics Announces Board Changes
9. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
10. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
11. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... and VANCOUVER, British Columbia ... OGXI ) announced today that it will report ... 14, 2015. Company management will host a conference call ... provide an overview of financial results, clinical development programs ... access the webcast, log on to the Investor Relations ...
(Date:5/4/2015)... , May 4, 2015  BioSpecifics Technologies Corp. ... in class collagenase-based products marketed as XIAFLEX ® ... XIAPEX ®  in the EU, will announce its first ... U.S. financial markets on Monday, May 11, 2015 and ... a.m. ET the next day, Tuesday May 12, 2015.  ...
(Date:5/4/2015)... N.J. , May 4, 2015 PTC Therapeutics, ... and reported financial results for the first quarter ending March ... strong start this year. In our first full quarter since ... to Translarna, the first treatment for nonsense mutation Duchene Muscular ... double the number on treatment since our last earnings call," ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. to Report First Quarter 2015 Financial Results on Monday, May 11, 2015 2PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 9
... YORK , June 22, 2011 The Alzheimer,s ... awarded a grant to Axxam SpA to develop small ... (Logo: http://photos.prnewswire.com/prnh/20090805/DC57332LOGO ) The ... compounds that block the puringeric receptor, P2X7, which is ...
... (NYSE: AGN ) today announced a new ... Obesity and Related Diseases that found the cost ... Allergan,s LAP-BAND® Adjustable Gastric Banding System, was offset by ... surgery eligible patients with diabetes, and within four years ...
Cached Medicine Technology:Alzheimer's Drug Discovery Foundation Supports Axxam To Develop Novel Therapeutics for Alzheimer's Disease 2New Study Finds That Gastric Banding Pays for Itself In Approximately Two Years for Patients With Diabetes and Four Years for Patients Without Diabetes 2New Study Finds That Gastric Banding Pays for Itself In Approximately Two Years for Patients With Diabetes and Four Years for Patients Without Diabetes 3New Study Finds That Gastric Banding Pays for Itself In Approximately Two Years for Patients With Diabetes and Four Years for Patients Without Diabetes 4New Study Finds That Gastric Banding Pays for Itself In Approximately Two Years for Patients With Diabetes and Four Years for Patients Without Diabetes 5New Study Finds That Gastric Banding Pays for Itself In Approximately Two Years for Patients With Diabetes and Four Years for Patients Without Diabetes 6
(Date:5/5/2015)... San Rafael, CA (PRWEB) May 05, 2015 ... Snader in 2012, with the belief that ultimate Frisbee™ ... can be the next sport that engages the world. ... the youth level, by creating opportunities for young athletes ... makes this collaboration with MLU the perfect fit. , ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 NovaSom, Inc., ... upcoming episode of Innovations with Ed Begley Jr., airing ... times TBA. , This segment will focus on NovaSom, ... Viewers will learn about their AccuSom® home sleep test, ... that provides continuous patient support and next-day test results ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Every year, news ... seasons. Turns out, the worst dry eye season is spring, ... spikes in most of the United States. The only season ... water advocate Sharon Kleyne, host of the Sharon Kleyne Hour™ ... on her radio show of May 11, 2015. Kleyne is ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 McMunn ... and end-to-end automation solutions, announced today that it has ... and corporate identity. According to president and founder, Larry ... aligned with the company’s strategy for growth and expansion ... successful for the past 30 years by building close, ...
(Date:5/5/2015)... BioFit Engineered Products , a globally ... from its two latest lines at NeoCon 2015, June ... Headlining the company’s exhibit will be new Pro and ... well as the unveiling of the fifth model of ... Metzger will deliver in-booth presentations each day of the ...
Breaking Medicine News(10 mins):Health News:US Sports Camps, Nike Ultimate Camps, and Major League Ultimate Host Youth Ultimate Summer Camps in Philidelphia 2Health News:Innovations with Ed Begley, Jr. to Explore NovaSom, Inc., in Upcoming Episode 2Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 2Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 3Health News:McMunn Associates Launches New Corporate Branding with New Website 2Health News:BioFit to Introduce New Models from Latest Specialized Ergonomic Seating Lines at NeoCon 2015 2Health News:BioFit to Introduce New Models from Latest Specialized Ergonomic Seating Lines at NeoCon 2015 3
... D. Eilers Professor of Medicine and Health Care Management and ... the Wharton School, was presented with the Alpha Omega Alpha ... of Medical Colleges (AAMC). The award was presented on ... Recognizing Dr. Asch, the AAMC said, "Dr. ...
... don,t help those with existing disease , TUESDAY, Nov. ... from a young age might prevent early signs of ... study in mice. , Recent research suggests that the ... in the development of Alzheimer,s. In the new study, ...
... ... Dr Cheryl Effron of Cosmetic Dermatology of Orange County offers Sculptra Aesthetic@ at affordable ... (PRWEB) ... of Cosmetic Dermatology of Orange County offers Sculptra Aesthetic@ at affordable prices., , , ...
... ... to have policyholders select and pay extra for either a plan which covers abortion or ... ... over abortion coverage and the possibility that the same thing could happen again in the ...
... ... a North American company, is expanding its cutting edge vibration exercise technology into South ... the Pro Elite, Air Reflex and Contour Plus, are now available in South America. ... (Vocus) November ...
... ATLANTA Emory University Rollins School of Public Health ... topics at the American Public Health Association,s annual meeting ... national recommendations that a physician screen chest pain patients ... Department (ED). Additional public health research findings from ...
Cached Medicine News:Health News:David A. Asch, M.D., M.B.A., receives AAMC Distinguished Teacher Award 2Health News:FDA-Approved Sculptra@ Now Offers by Orange County Dermatologist Dr. Cheryl Effron 2Health News:“Think Outside the Box” Blog Proposes Better Abortion Compromise for Health Reform 2Health News:WAVE's Revolutionary Whole-Body Advanced Vibration Exercise Is Now Available in South America 2Health News:Some chest pain patients wait longer than 10 minutes to see ER physician 2
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
Inquire...
... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features:Eppendorf "pipette/tip" system ensures ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
Medicine Products: